Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 94 Glioma 32 Brain Neoplasms 29 Melanoma 21 Neoplasms 17 Astrocytoma 17 Sarcoma, Ewing 7 Ovarian Neoplasms 7 Gliosarcoma 7 Carcinoma, Non-Small-Cell Lung 7 Neuroblastoma 6 Neoplasm Metastasis 6 Medulloblastoma 6 Breast Neoplasms 6 Sarcoma 5 Recurrence 5 Diffuse Intrinsic Pontine Glioma 5 Small Cell Lung Carcinoma 4 Rhabdomyosarcoma 4 Oligodendroglioma 4 Spinal Cord Neoplasms 3 Prostatic Neoplasms 3 Pancreatic Neoplasms 3 Central Nervous System Neoplasms 3 Triple Negative Breast Neoplasms 2 Rhabdoid Tumor 2 Neuroendocrine Tumors 2 Lymphoma, Follicular 2 Head and Neck Neoplasms 2 Fallopian Tube Neoplasms 2

Interventions

pembrolizumab 3 relatlimab 1 lifileucel 1 dabrafenib 1 Temozolomide 1 Paclitaxel 1 Opdualag 1 Nivolumab 1 Ipilimumab 1 Dacarbazine 1 Carboplatin 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Melanoma, Cutaneous Malignant × Temozolomide × Clear all

NCT06743126 2026-05-29

SUPRAME

Immatics US, Inc.

Phase 3 Recruiting

Melanoma, Cutaneous Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡